Amgen – Amgen : Says Breakthrough Therapy Designation Given for Sotorasib In China
By Stephen Nakrosis
Amgen Inc. on Friday said its sotorasib received Breakthrough Therapy Designation in China from the Center for Drug Evaluation of the National Medical Products Administration.
The company said sotorasib is an investigational KRAS(G12C) inhibitor.
“The designation is for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy,” Amgen said.
The company said this was its first Breakthrough Therapy Designation submission in China and the first under its strategic collaboration with BeiGene.
Amgen said non-small cell lung cancer is the most common form of lung cancer, accounting for about 80-85% of all cases worldwide.
–Write to Stephen Nakrosis at firstname.lastname@example.org
(END) Dow Jones Newswires